ARCT News and Press, Arcturus Therapeutics Ltd. From 06/30/22

Gainers: Inter &  ( INTR ) +34% . Cytokinetics ( CYTK ) +6% . MSP Recovery ( MSPR ) +6% . Ocular Therapeutix ( OCUL ) +5% . Kirkland's ( KIRK ) +5% . Losers: Microvast Holdings ( MVST ) -7% . Virgin O...

Arcturus Therapeutics (NASDAQ:ARCT) is said to have been approached about a takeover by CSL Limited (OTCPK:CSLLY), a source reportedly told Street Insider, whose account added that it is "unclear if the rumored talks will lead to a definitive deal." Shares of Arcturus was up 8% on take o...

An EUA for ARCT-154 as a COVID-19 vaccine in Vietnam has been submitted, with expected approval in 2022. A phase 2 study using ARCT-810 as a treatment option for patients with OTC deficiency is expected to start in mid-2022; results are then expected 2nd half of 2022. A CTA to beg...

Gainers: Avadel Pharmaceuticals (AVDL) +123%. SIGA Technologies (SIGA) +40%. Concert Pharmaceuticals (CNCE) +30%. Farfetch (FTCH) +25%. Allarity Therapeutics (ALLR) +25%. Merus N.V. (MRUS) +23%. Tenon Medical (TNON) +22%. Arcturus Therapeutics Holdings (ARCT) +19%. Red Rob...

Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2022 Results Earnings Conference Call May 9, 2022, 04:30 PM ET Company Participants Deepankar Roy - Senior Director, Investor Relations Joseph Payne - President and Chief Executive Officer Andrew Sassine - Chief Financial Officer Pad Chivukula - C...

Arcturus Therapeutics press release (NASDAQ:ARCT): Q1 GAAP EPS of -$1.94 misses by $0.63. Revenue of $5.24M (+146.0% Y/Y) misses by $1.84M. For further details see: Arcturus Therapeutics GAAP EPS of -$1.94 misses by $0.63, revenue of $5.24M misses by $1.84M

ARCT-154 booster data show 54- and 46-fold increases in neutralizing antibody response against Omicron BA.1 and BA.2 Investor conference call at 4:30 p.m. ET today Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARC...

Arcturus Therapeutics (NASDAQ:ARCT) is scheduled to announce Q1 earnings results on Monday, May 9th, after market close. The consensus EPS Estimate is -$1.40 (+34.9% Y/Y) and the consensus Revenue Estimate is $7.08M (+232.4% Y/Y). Over the last 3 months, EPS estimates have seen 5 upward revis...

Three-month data from ARCT-154 booster trial show persistent neutralizing antibody activity against multiple variants of SARS-CoV-2 International pivotal Phase 3 booster trial preparations initiated with global CRO Please replace the graphic with the accompanying cor...

Three-month data from ARCT-154 booster trial show persistent neutralizing antibody activity against multiple variants of SARS-CoV-2 International pivotal Phase 3 booster trial preparations initiated with global CRO Arcturus Therapeutics Holdings Inc. (the “Com...